Ex1 Chart, page-69

There's just so much to like about this company.

FDA approval quickly followed by what seems a close collaboration with a Top 20 bio company in the US. Contrary to the BS you read on here important milestones have been achieved in the relatively short time since listing. They know what the prize is and they'll get there.

Dixon has shown his ruthless side and appointed people who can pick up the phone and talk to bio execs around the world.

As far as CR's go ,of course there'll be CR's. It's as if some people are completely ignorant about how developing bios or even established ones have to operate. If the company progresses as I'm sure it will this year any CR will be swallowed up. Like the last one. Which in hindsight was a bit early but so what. Anyone invested will be happy in the end.

Reading between the lines there could be more coming . You don't get money and a tie up with the opportunity to work in their own labs on their own products with someone like Astellas unless they have a degree of confidence about the outcomes.

In the meantime just be patient.

Read carefully the blurb on the Leap patent granted in the quarterly. If they pull it off this is major stuff for a $70 mill Aud. company